In clinical terms, the overall effect of these antiresorptive agents is the increase in bone mass, reduction of hypercalcemia, stabilization of bone pathologies, improvement in bone quality, stabilization of bone pathologies, improvement in bone quality, and increased efficiency of orthodontic treatment. It is believed that the use of bisphosphonates can generate some kind of change in orthodontic movement. This is a short review about the influence of the use of bisphosphonates in orthodontic movement. Bisphosphonates act as regulators of bone metabolism, through the inhibition of osteoclastic activity, promoting a reduction of bone resorption, mainly through the induction of apoptosis in osteoclasts and the inhibition of maturation of these cells. In clinical terms, the overall effect of these agents is the increase in bone mass, reduction of hypercalcemia, stabilization of bone pathologies, improvement in bone strength and the risk reduction of pathological fracture.

The aging of the population, exposes the surgeon dentist each day more to care for this group with osteoporosis, therefore, it is up to the orthodontist to be informed of the potential impact of this class of drugs in our patients. The use in long-term of bisphosphonates to treat osteoporosis can lead to the accumulation of the drug in the bone. Once incorporated, the drug is released slowly during physiologic bone remodeling and in a greater degree during bone remodeling, i.e., in the processes associated with the orthodontic movement, increasing its absorption in localized areas of the maxilla and the mandible. This is probably going to bring adverse results in bone remodeling during dental movement attempts. In other words, they may be adverse events during the movement, in a bone filled with bisphosphonates, on account of the ability of the drug to interfere in the osteoclastic activity.

It is worth pointing out that the orthodontist should be attentive in obtaining the history of health of their patients, as well as in the history of the use of current and past medications to evaluate the limitations on decisions of treatment planning, in order to avoid the risk of bone necrosis associated with more extended dental movement. Although the risk of osteonecrosis, associated with the use of bisphosphonates in the mandible, for the treatment of osteoporosis, even small, the constant remodeling during the orthodontic movement along with bacterial colonization in the oral cavity, may predispose to an increased risk of osteonecrosis. It is worth remembering that potent intravenous bisphosphonates are also used in children for the treatment of osteopenia, Paget’s disease, osteogenesis imperfecta, malignant hypercalcemia, among others; and these patients may come to the orthodontist, which in this case, probably, can increase the risk of osteonecrosis related to the use of bisphosphonates.

It is advisable to clarify the patients and their caregivers regarding the impossibility of achieving an ideal orthodontic movement. The potential risks should be discussed and the informed consent should be obtained prior to the start of the orthodontic treatment. Depending on the category of patient’s risk (dose, route and duration of treatment with bisphosphonates), elective surgeries, dental extractions, surgery involving bone such as placing minis crews should be avoided, in addition to infections of dental and periodontal origin. If necessary the performance of invasive procedures, the physician should be consulted and the patient should be referred to a dental surgeon with experience in the area.

The use of bisphosphonates is not an absolute contraindication for the orthodontic treatment, especially for low-risk patients. However, the outcome of the treatment is still not predictable in high risk patients.

Dear editor,

This is a short review about the influence of the use of bisphosphonates in orthodontic movement. Bisphosphonates are synthetic drugs similar to pyrophosphate. These drugs have been used in the treatment of diseases that have an intense bone resorption, such as osteoporosis and Paget’s disease, as well as, in support therapy for bone tumors and bone metastases, as multiple myeloma, breast cancer and prostate cancer.

The orthodontic movement occurs through the controlled application of mechanical forces and the creation of a biological response in the tooth. The movement of the tooth is the result of events in the periodontal ligament and the surrounding alveolar bone area. Some pharmacological agents such as the bisphosphonates can alter the orthodontic movement when they are in sufficient concentration in the alveolar bone. It is known that the arrival of the osteoclasts is the first necessary step for the orthodontic movement, and that any interference in the function of these cells results in decreased efficiency of orthodontic treatment. In this way it is believed that the use of bisphosphonates can generate some kind of change in orthodontic movement.

These drugs act as regulators of bone metabolism, through the inhibition of osteoclastic activity, promoting a reduction of bone resorption, mainly through the induction of apoptosis in osteoclasts and the inhibition of maturation of these cells. In clinical terms, the overall effect of these agents is the increase in bone mass, reduction of hypercalcemia, stabilization of bone pathologies, improvement in bone strength and the risk reduction of pathological fracture.

The aging of the population, exposes the surgeon dentist each day more to care for this group with osteoporosis, therefore, it is up to the orthodontist to be informed of the potential impact of this class of drugs in our patients. The use in long-term of bisphosphonates to treat osteoporosis can lead to the accumulation of the drug in the bone. Once incorporated, the drug is released slowly during physiologic bone remodeling and in a greater degree during bone remodeling, i.e., in the processes associated with the orthodontic movement, increasing its absorption in localized areas of the maxilla and the mandible. This is probably going to bring adverse results in bone remodeling during dental movement attempts. In other words, they may be adverse events during the movement, in a bone filled with bisphosphonates, on account of the ability of the drug to interfere in the osteoclastic activity.

It is worth pointing out that the orthodontist should be attentive in obtaining the history of health of their patients, as well as in the history of the use of current and past medications to evaluate the limitations on decisions of treatment planning, in order to avoid the risk of bone necrosis associated with more extended dental movement. Although the risk of osteonecrosis, associated with the use of bisphosphonates in the mandible, for the treatment of osteoporosis, even small, the constant remodeling during the orthodontic movement along with bacterial colonization in the oral cavity, may predispose to an increased risk of osteonecrosis. It is worth remembering that potent intravenous bisphosphonates are also used in children for the treatment of osteopenia, Paget’s disease, osteogenesis imperfecta, malignant hypercalcemia, among others; and these patients may come to the orthodontist, which in this case, probably, can increase the risk of osteonecrosis related to the use of bisphosphonates.

It is advisable to clarify the patients and their caregivers regarding the impossibility of achieving an ideal orthodontic movement. The potential risks should be discussed and the informed consent should be obtained prior to the start of the orthodontic treatment. Depending on the category of patient’s risk (dose, route and duration of treatment with bisphosphonates), elective surgeries, dental extractions, surgery involving bone such as placing minis crews should be avoided, in addition to infections of dental and periodontal origin. If necessary the performance of invasive procedures, the physician should be consulted and the patient should be referred to a dental surgeon with experience in the area.

The use of bisphosphonates is not an absolute contraindication for the orthodontic treatment, especially for low-risk patients. However, the outcome of the treatment is still not predictable in high risk patients.
Influence of bisphosphonates at orthodontic movement

References


Mini Curriculum and Author’s Contribution

1. Rosany Larissa Brito de Oliveira – DDS. Contribution: data collect and article writing.
2. Francisco de Assis Lúcio Sant’ana – MSc. Contribution: data collect.
5. Valtuir Barbosa Felix – DDS and PhD. Contribution: article design and article writing.

Submitted: 07/24/2017 / Accepted for publication: 08/18/2017

Corresponding Author
Paulo Sérgio da Silva Santos
E-mail: paulosergiosilvasantos@gmail.com